About this trial
The main pathological mechanism of Alzheimer's Disease (AD) is the abnormal deposition of amyloid-beta (Aβ) and tau proteins in the brain. Recent studies indicate that these two proteins are primarily cleared through the glymphatic system-meningeal lymphatic vessels-deep cervical lymphatic vessels pathway. Lymphatic circulation disorders in elderly patients can directly lead to the abnormal deposition of these proteins. Deep cervical lymphovenous bypass can improve lymphatic circulation and effectively treat lymphedema. This project aims to verify the effectiveness of 'deep cervical lymphovenous bypass' in treating AD, offering a new surgical treatment method to improve cognitive impairment and the quality of life for AD patients.
Eligibility criteria
Qualifiers
The age ranged from 60 to 80 years, and the time from initial diagnosis to enrollment was more than 12 months
The estimated survival time is more than 12 months;
The clinically diagnosed patients with mild to severe Alzheimer's Disease;
The imaging examination has the correlation diagnosis evidence;
Disqualifiers
Complicated with other severe systemic underlying diseases;
Unable to tolerate general anesthesia;
The pregnant women;
Recent severe infection or infectious diseases within 4 weeks;
Trial design
Treatments tested in this trial
- Deep cervical Lymphovenous Bypass